Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II galunisertib + capecitabine in chemotherapy-resistant colorectal cancer with peritoneal metastases
2024-518980-37-00Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galunisertib and capecitabine in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and RP2D in Phase I and Objective response rate in Phase II. Started Jan 2025; status: completed.
02
Drugs
galunisertibcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-518980-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518980-37-00.